A Study of Olverembatinib Combined With Inotuzumab Ozogamicin in the Treatment ph+ ALL With MRD Persistent Positive
Clinical trial NCT05603156 · UNKNOWN
Trial details
- NCT number
- NCT05603156
- Sponsor
- Institute of Hematology & Blood Diseases Hospital, China
- Status
- UNKNOWN
- Phase
- Not Applicable
- Study type
- INTERVENTIONAL
- Start date
- 2022-10-30
- Primary completion
- 2024-07-31
- Enrollment
- 46
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.